1. 4443 Tailoring Professional Development to CTS Trainees. Issue Volume 4:Issue(2020)Supplement 1 (June 2020) Authors: Maxwell, Megan; Hexner, Elizabeth; McGarrigle, Rachel; Meagher, Emma Journal: Journal of clinical and translational science Issue: Volume 4:Issue(2020)Supplement 1 Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cancer Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells. Issue 3 (November 2017) Authors: Littman, Dalia; Hexner, Elizabeth Journal: Journal of onco-nephrology Issue: Volume 1:Issue 3(2017) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32. Issue 12 (December 2018) Authors: Babushok, Daria; Stanley, Natasha; Morrissette, Jennifer; Lieberman, David; Olson, Timothy; Chou, Stella; Hexner, Elizabeth Journal: Leukemia Issue: Volume 32:Issue 12(2018) Page Start: 2720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Issue 9 (September 2022) Authors: DeZern, Amy E; Eapen, Mary; Wu, Juan; Talano, Julie-An; Solh, Melhem; Dávila Saldaña, Blachy J; Karanes, Chatchada; Horwitz, Mitchell E; Mallhi, Kanwaldeep; Arai, Sally; Farhadfar, Nosha; Hexner, Elizabeth; Westervelt, Peter; Antin, Joseph H; Deeg, H Joachim; Leifer, Eric; Brodsky, Robert A; Loga... Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. JAK2 V617F‐positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. (16th May 2018) Authors: Aynardi, Jason; Manur, Rashmi; Hess, Paul R.; Chekol, Seble; Morrissette, Jennifer J. D.; Babushok, Daria; Hexner, Elizabeth; Rogers, Heesun J.; Hsi, Eric D.; Margolskee, Elizabeth; Orazi, Attilio; Hasserjian, Robert; Bagg, Adam Journal: British journal of haematology Issue: Volume 182:Number 1(2018) Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Open‐label study of oral CEP‐701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2‐V617F mutation. (28th October 2013) Authors: Hexner, Elizabeth; Roboz, Gail; Hoffman, Ron; Luger, Selina; Mascarenhas, John; Carroll, Martin; Clementi, Regina; Bensen‐Kennedy, Debra; Moliterno, Alison Journal: British journal of haematology Issue: Volume 164:Number 1(2014:Jan.) Page Start: 83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report. Issue 1 (December 2016) Authors: Lewen, Margaret; Gresh, Renee; Queenan, Maria; Paessler, Michele; Pillai, Vinodh; Hexner, Elizabeth; Frank, Dale; Bagg, Adam; Aplenc, Richard; Caywood, Emi; Wertheim, Gerald Journal: Biomarker research Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Issue 4 (3rd April 2023) Authors: Freyer, Craig W.; Hughes, Mitchell E.; Carulli, Alison; Bagg, Adam; Hexner, Elizabeth Journal: Expert review of anticancer therapy Issue: Volume 23:Issue 4(2023) Page Start: 351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Issue 5 (16th April 2019) Authors: Mascarenhas, John; Baer, Maria R.; Kessler, Craig; Hexner, Elizabeth; Tremblay, Douglas; Price, Leah; Sandy, Lonette; Weinberg, Rona; Pahl, Heike; Silverman, Lewis R.; Goldberg, Judith D.; Kosiorek, Heidi; Dueck, Amylou C.; Hoffman, Ronald Journal: Leukemia & lymphoma Issue: Volume 60:Issue 5(2019) Page Start: 1343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. (11th March 2013) Authors: Verstovsek, Srdan; Mesa, Ruben A.; Gotlib, Jason; Levy, Richard S.; Gupta, Vikas; DiPersio, John F.; Catalano, John V.; Deininger, Michael; Miller, Carole; Silver, Richard T.; Talpaz, Moshe; Winton, Elliott F.; Harvey, Jimmie H.; Arcasoy, Murat O.; Hexner, Elizabeth; Lyons, Roger M.; Paquette, Ro... Journal: British journal of haematology Issue: Volume 161:Number 4(2013:May) Page Start: 508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗